NATURALENDO TECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,620 KRW | +1.55% |
|
+2.95% | +30.67% |
| Sales 2022 | 13.95B 10.07M 13.85M | Sales 2023 | 18.79B 13.57M 18.66M | Capitalization | 63.3B 45.71M 62.86M |
|---|---|---|---|---|---|
| Net income 2022 | -10.08B -7.28M -10.01M | Net income 2023 | -4.37B -3.15M -4.34M | EV / Sales 2022 | 6.86 x |
| Net cash position 2022 | 6.89B 4.98M 6.84M | Net cash position 2023 | 705M 509K 700K | EV / Sales 2023 | 3.33 x |
| P/E ratio 2022 |
-10.1
x | P/E ratio 2023 |
-14.5
x | Employees | 71 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 51.18% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.55% | ||
| 1 week | +2.95% | ||
| Current month | +10.08% | ||
| 1 month | +10.08% | ||
| 3 months | +27.49% | ||
| 6 months | +25.66% | ||
| Current year | +30.67% |
1 week
2 500.00
2 670.00
1 month
2 305.002 845.00
Current year
1 991.002 845.00
1 year
1 896.003 100.00
3 years
1 896.0012 000.00
5 years
1 896.0012 000.00
10 years
1 896.0091 200.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hee-Do Kim
CEO | Chief Executive Officer | 50 | - |
| - | - | ||
Seon-Hui Lee
AUD | Comptroller/Controller/Auditor | 72 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joo-Hwan Yang
BRD | Director/Board Member | 72 | 21-06-09 |
Geum-Deok Park
BRD | Director/Board Member | 65 | - |
Hee-Do Kim
CEO | Chief Executive Officer | 50 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 2,620 | +1.55% | 67 932 |
| 24-04-29 | 2,580 | +0.98% | 41,592 |
| 24-04-26 | 2,555 | -1.35% | 47,928 |
| 24-04-25 | 2,590 | -1.15% | 113,781 |
| 24-04-24 | 2,620 | +1.95% | 51,173 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Naturalendo Tech Co.,Ltd. is a Korea-based company principally engaged in the research and development (R&D) and manufacture of hormone biotechnology products. The Company mainly provides novel phytoestrogen, which is applied in the treatment of climacteric. It also provides other hormonal formula, such as hormone disruptor inhibitor, secretagogue and inhibitor used as diet formula and growth hormone. In addition, the Company provides materials used for diet, and involves in the R&D of drug delivery systems, immune enhancer, atopy and acne, plantation factory, and others.
Sector
Personal Products
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +30.67% | 59.22M | |
| -2.44% | 250B | |
| +12.50% | 18.94B | |
| 0.00% | 17.84B | |
| -0.87% | 10.7B | |
| -7.79% | 10.31B | |
| +16.90% | 6.95B | |
| +10.15% | 5.98B | |
| -0.89% | 4.56B | |
| -18.88% | 3.77B |
- Stock Market
- Equities
- A168330 Stock
